Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis

References

• WHO. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022.
   Google Scholar
• Sloan DJ, Davies GR, Khoo SH. Recent advances in tuberculosis: new drugs and treatment regimens. Curr Respir Med Rev. 2013;9(3):200–210. doi: 10.2174/1573398x113099990017.
   PubMedGoogle Scholar
• Francis J, Zvada SP, Denti P, et al. A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine. Antimicrob Agents Chemother. 2019;63(4):e01964-18. doi: 10.1128/AAC.01964-18.
   PubMed Web of Science ®Google Scholar
• Chakaya J, Khan M, Ntoumi F, et al. Global Tuberculosis Report 2020 – reflections on the global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021;113(Suppl 1):S7–S12. doi: 10.1016/j.ijid.2021.02.107.
   PubMedGoogle Scholar
• Molla KA, Reta MA, Ayene YY. Prevalence of multidrug-resistant tuberculosis in East Africa: a systematic review and meta-analysis. PLoS One. 2022;17(6):e0270272. doi: 10.1371/journal.pone.0270272.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007;51(8):2994–2996. doi: 10.1128/AAC.01474-06.
   PubMed Web of Science ®Google Scholar
• Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51(11):3781–3788. doi: 10.1128/AAC.01533-06.
   PubMed Web of Science ®Google Scholar
• Niward K, Davies Forsman L, Bruchfeld J, et al. Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. J Antimicrob Chemother. 2018;73(10):2838–2845. doi: 10.1093/jac/dky268.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Chandrasekaran P, Gaikwad S, et al. Subtherapeutic rifampicin concentration is associated with unfavorable tuberculosis treatment outcomes. Clin Infect Dis. 2020;70(7):1463–1470. doi: 10.1093/cid/ciz380.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Fukami T, Kobayashi Y, et al. Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol. 2011;82(11):1747–1756. doi: 10.1016/j.bcp.2011.08.003.
   PubMed Web of Science ®Google Scholar
• Mukonzo JK, Kengo A, Kutesa B, et al. Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients. Trans R Soc Trop Med Hyg. 2020;114(2):107–114. doi: 10.1093/trstmh/trz108.
   PubMed Web of Science ®Google Scholar
• Sileshi T, Tadesse E, Makonnen E, et al. The impact of first-line anti-tubercular drugs’ pharmacokinetics on treatment outcome: a systematic review. Clin Pharmacol. 2021;13:1–12. doi: 10.2147/CPAA.S289714.
   PubMed Web of Science ®Google Scholar
• Song SH, Chang HE, Jun SH, et al. Relationship between CES2 genetic variations and rifampicin metabolism. J Antimicrob Chemother. 2013;68(6):1281–1284. doi: 10.1093/jac/dkt036.
   PubMed Web of Science ®Google Scholar
• Weiner M, Gelfond J, Johnson-Pais TL, et al. Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis. J Antimicrob Chemother. 2021;76(3):582–586. doi: 10.1093/jac/dkaa490.
   PubMed Web of Science ®Google Scholar
• Sloan DJ, McCallum AD, Schipani A, et al. Genetic determinants of the pharmacokinetic variability of rifampin in Malawian adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2017;61(7):e00210-17. doi: 10.1128/AAC.00210-17.
   PubMed Web of Science ®Google Scholar
• Dompreh A, Tang X, Zhou J, et al. Effect of genetic variation of NAT2 on isoniazid and SLCO1B1 and CES2 on rifampin pharmacokinetics in Ghanaian children with tuberculosis. Antimicrob Agents Chemother. 2018;62(3):e02099-17. doi: 10.1128/AAC.02099-17.
   Web of Science ®Google Scholar
• Tirona RG, Leake BF, Wolkoff AW, et al. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003;304(1):223–228. doi: 10.1124/jpet.102.043026.
   PubMed Web of Science ®Google Scholar
• Williamson B, Dooley KE, Zhang Y, et al. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother. 2013;57(12):6366–6369. doi: 10.1128/AAC.01124-13.
   PubMed Web of Science ®Google Scholar
• Thomas L, Sekhar Miraj S, Surulivelrajan M, et al. Influence of single nucleotide polymorphisms on rifampin pharmacokinetics in tuberculosis patients. Antibiotics (Basel). 2020;9(6):307. doi: 10.3390/antibiotics9060307.
   Web of Science ®Google Scholar
• Sileshi T, Mekonen G, Makonnen E, et al. Effect of genetic variations in drug-metabolizing enzymes and drug transporters on the pharmacokinetics of rifamycins: a systematic review. Pharmgenomics Pers Med. 2022;15:561–571. doi: 10.2147/PGPM.S363058.
   PubMed Web of Science ®Google Scholar
• Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother. 2011;55(9):4122–4127. doi: 10.1128/AAC.01833-10.
   PubMed Web of Science ®Google Scholar
• Weiner M, Peloquin C, Burman W, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother. 2010;54(10):4192–4200. doi: 10.1128/AAC.00353-10.
   PubMed Web of Science ®Google Scholar
• Aklillu E, Habtewold A, Ngaimisi E, et al. SLCO1B1 gene variations among Tanzanians, Ethiopians, and Europeans: relevance for African and worldwide precision medicine. OMICS. 2016;20(9):538–545. doi: 10.1089/omi.2016.0119.
   PubMed Web of Science ®Google Scholar
• Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11(3):217–221. doi: 10.1097/00008571-200104000-00005.
   PubMedGoogle Scholar
• Mugusi S, Habtewold A, Ngaimisi E, et al. Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis Co-therapy: a parallel prospective cohort study in two Sub-Sahara African populations. Front Pharmacol. 2020;11:26. doi: 10.3389/fphar.2020.00026.
   PubMed Web of Science ®Google Scholar
• Aklillu E, Mugusi S, Ngaimisi E, et al. Frequency of the SLCO1B1 388A > G and the 521T > C polymorphism in Tanzania genotyped by a new LightCycler®-based method. Eur J Clin Pharmacol. 2011;67(11):1139–1145. doi: 10.1007/s00228-011-1065-9.
   PubMed Web of Science ®Google Scholar
• EFMOH (Ethiopia Federal Ministry of Health). Guidelines for clinical and programmatic management of TB, TB/HIV, DR-TB and leprosy in Ethiopia. 2021. Available from: http://repository.iphce.org/xmlui/handle/123456789/1662
   Google Scholar
• Chala A, Tadesse BT, Chaka TE, et al. Predictors of efavirenz plasma exposure, auto-induction profile, and effect of pharmacogenetic variations among HIV-Infected children in Ethiopia: a prospective cohort study. J Pers Med. 2021;11(12):1303. doi: 10.3390/jpm11121303.
   PubMed Web of Science ®Google Scholar
• FDA. Statistical approaches to establishing bioequivalence. Guidance for industry. 2001. Available from: https://www.fda.gov/media/70958/download
   Google Scholar
• Dunvald AD, Iversen DB, Svendsen ALO, et al. Tutorial: statistical analysis and reporting of clinical pharmacokinetic studies. Clin Transl Sci. 2022;15(8):1856–1866. doi: 10.1111/cts.13305.
   PubMed Web of Science ®Google Scholar
• Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839–854. doi: 10.1007/s40265-014-0222-8.
   PubMed Web of Science ®Google Scholar
• Chawla PK, Udwadia ZF, Soman R, et al. Importance of therapeutic drug monitoring of rifampicin. J Assoc Physicians India. 2016;64(8):68–72.
   PubMedGoogle Scholar
• Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169–2183. doi: 10.2165/00003495-200262150-00001.
   PubMed Web of Science ®Google Scholar
• Prahl JB, Johansen IS, Cohen AS, et al. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J Antimicrob Chemother. 2014;69(10):2841–2847. doi: 10.1093/jac/dku210.
   PubMed Web of Science ®Google Scholar
• Trentalange A, Borgogno E, Motta I, et al. Rifampicin and isoniazid maximal concentrations are below efficacy-associated thresholds in the majority of patients: time to increase the doses? Int J Antimicrob Agents. 2021;57(3):106297. doi: 10.1016/j.ijantimicag.2021.106297.
   PubMed Web of Science ®Google Scholar
• van Crevel R, Alisjahbana B, de Lange WC, et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int J Tuberc Lung Dis. 2002;6(6):497–502. doi: 10.5588/09640569513002.
   PubMed Web of Science ®Google Scholar
• Niward K, Ek Blom L, Davies Forsman L, et al. Plasma levels of rifampin correlate with the tuberculosis drug activity assay. Antimicrob Agents Chemother. 2018;62(5):e00218-18. doi: 10.1128/AAC.00218-18.
   PubMed Web of Science ®Google Scholar
• Asgedom SW, Teweldemedhin M, Gebreyesus H. Prevalence of Multidrug-Resistant tuberculosis and associated factors in Ethiopia: a systematic review. J Pathog. 2018;2018:7104921–7104928. doi: 10.1155/2018/7104921.
   PubMedGoogle Scholar
• Mehari K, Asmelash T, Hailekiros H, et al. Prevalence and factors associated with multidrug-resistant tuberculosis (MDR-TB) among presumptive MDR-TB patients in Tigray region, Northern Ethiopia. Can J Infect Dis Med Microbiol. 2019;2019:2923549. doi: 10.1155/2019/2923549.
   PubMed Web of Science ®Google Scholar
• Stott KE, Pertinez H, Sturkenboom MGG, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73(9):2305–2313. doi: 10.1093/jac/dky152.
   PubMed Web of Science ®Google Scholar
• Garcia-Prats AJ, Svensson EM, Winckler J, et al. Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. J Antimicrob Chemother. 2021;76(12):3237–3246. doi: 10.1093/jac/dkab336.
   PubMed Web of Science ®Google Scholar
• Velásquez GE, Brooks MB, Coit JM, et al. Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled trial. Am J Respir Crit Care Med. 2018;198(5):657–666. doi: 10.1164/rccm.201712-2524OC.
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang T, He K, et al. High-dose rifampicin for the treatment of tuberculous meningitis: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2022;47(4):445–454. doi: 10.1111/jcpt.13555.
   PubMed Web of Science ®Google Scholar
• Onorato L, Gentile V, Russo A, et al. Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(6):830–837. doi: 10.1016/j.cmi.2021.03.031.
   PubMed Web of Science ®Google Scholar
• Polasa K, Murthy KJ, Krishnaswamy K. Rifampicin kinetics in undernutrition. Br J Clin Pharmacol. 1984;17(4):481–484. doi: 10.1111/j.1365-2125.1984.tb02377.x.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Kumar AK, Kannan T, et al. Low serum concentrations of rifampicin and pyrazinamide associated with poor treatment outcomes in children with tuberculosis related to HIV status. Pediatr Infect Dis J. 2016;35(5):530–534. doi: 10.1097/INF.0000000000001069.
   PubMed Web of Science ®Google Scholar
• Tostmann A, Mtabho CM, Semvua HH, et al. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. Antimicrob Agents Chemother. 2013;57(7):3208–3213. doi: 10.1128/AAC.02599-12.
   PubMed Web of Science ®Google Scholar
• Aklillu E, Zumla A, Habtewold A, et al. Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. Br J Pharmacol. 2021;178(16):3294–3308. doi: 10.1111/bph.15309.
   PubMed Web of Science ®Google Scholar
• Ngaimisi E, Habtewold A, Minzi O, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One. 2013;8(7):e67946. doi: 10.1371/journal.pone.0067946.
   PubMed Web of Science ®Google Scholar
• Aklillu E, Djordjevic N, Carrillo JA, et al. High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS. 2014;18(7):446–453. doi: 10.1089/omi.2013.0140.
   PubMed Web of Science ®Google Scholar
• Sileshi T, Telele NF, Burkley V, et al. Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in Ethiopian tuberculosis patients. Sci Rep. 2023;13(1):11438. doi: 10.1038/s41598-023-38716-3.
   PubMed Web of Science ®Google Scholar
• Gengiah TN, Botha JH, Soowamber D, et al. Low rifampicin concentrations in tuberculosis patients with HIV infection. J Infect Dev Ctries. 2014;8(8):987–993. doi: 10.3855/jidc.4696.
   PubMed Web of Science ®Google Scholar
• Naidoo A, Chirehwa M, Ramsuran V, et al. Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. Pharmacogenomics. 2019;20(4):225–240. doi: 10.2217/pgs-2018-0166.
   PubMed Web of Science ®Google Scholar
• Medellin-Garibay SE, Huerta-Garcia AP, Rodriguez-Baez AS, et al. A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis. Tuberculosis. 2020;124:101982. doi: 10.1016/j.tube.2020.101982.
   PubMed Web of Science ®Google Scholar
• Sissung TM, Baum CE, Kirkland CT, et al. Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010;44(2):152–167. doi: 10.1007/s12033-009-9220-6.
   PubMed Web of Science ®Google Scholar
• Huerta-García AP, Medellín-Garibay SE, Salazar-González RA, et al. Anthropometric and genetic factors associated with the exposure of rifampicin and isoniazid in Mexican patients with tuberculosis. Ther Drug Monit. 2019;41(5):648–656. doi: 10.1097/FTD.0000000000000631.
   PubMed Web of Science ®Google Scholar
• Levano KS, Jaramillo-Valverde L, Tarazona DD, et al. Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients. Mol Genet Genomic Med. 2021;9(10):e1764.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Rustomjee R, Vahedi M, et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012;56(6):3232–3238. doi: 10.1128/AAC.05526-11.
   PubMed Web of Science ®Google Scholar
• Cojutti P, Giangreco M, Isola M, et al. Limited sampling strategies for determining the area under the plasma concentration-time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis. Int J Antimicrob Agents. 2017;50(1):23–28. doi: 10.1016/j.ijantimicag.2017.01.036.
   PubMed Web of Science ®Google Scholar
• Maganda BA, Minzi OM, Ngaimisi E, et al. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. Pharmacogenomics J. 2016;16(1):88–95. doi: 10.1038/tpj.2015.37.
   PubMed Web of Science ®Google Scholar